Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Onyx Pharmaceuticals (UNKNOWN:UNKNOWN), a cancer-focused biopharmaceutical company, shot higher by as much as 10% after the company reported better-than-expected fourth-quarter results.
So what: For the quarter, Onyx reported revenue of $127.9 million and a loss of $0.36 per share. Revenue was down 46% year-over-year; however, the year-ago period included revenue from the sale of its royalty rights to Nexavar in Japan for $160 million. Wall Street had been projecting that Onyx would lose $0.76 per share. Newly approved second-line multiple myeloma treatment Kyprolis saw sales grow to $45.3 million for the quarter, or 242% higher than the sequential third quarter.
Now what: Things are going really well for Onyx Pharmaceuticals. Royalties from its liver and kidney cancer drug, Nexavar, grew 2.6% for the full year, excluding Japan, and Kyprolis is off to what I consider a fantastic start. There's a little concern for Kyprolis now that Celgene's (NASDAQ:CELG) Pomalyst is also approved as a second-line treatment for multiple myeloma, but I'm more of the opinion that with so few options existing beyond the initial multiple myeloma treatments, that the market will expand to more than accommodate sales growth for both drugs.
Craving more input? Start by adding Onyx Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.